Continuous Subcutaneous Hydrocortisone Infusion in Adrenal Insufficiency: Practical Experience in 33 Subjects
Authors' conclusion
CSHI is a safe and effective means of delivering individualized glucocorticoid therapy to pwAI.
Study context
- Population
- Consecutive people with AI offered a therapeutic trial of continuous subcutaneous hydrocortisone infusion (CSHI) due to persistent AI symptoms; 82% women; primary AI 27.3%, secondary AI 48.5%, glucocorticoid-induced AI 24.2%
- Participants
- 33 people
- Exposure
- Before vs after switching to CSHI
- Outcome
- Total daily glucocorticoid dose (hydrocortisone equivalent)
- Follow-up
- Before CSHI, CSHI initiation and last encounter
Methodological detailssingle-center, longitudinal, consecutive patients
- Single-center
- Longitudinal
- Consecutive patients
Main finding
As reported in the abstract
Pre-CSHI
30
median · range 15-180 mg · mg/d
mg/d
- Median dose at CSHI initiation (P = .013)
- 26.7
- Median dose at last encounter (P = .023)
- 26.6
Observational data: associations, not effects.
Further findings
Median
| Outcome | Pre-CSHI | CSHI | P value |
|---|---|---|---|
| ED visits/year due to adrenal crisis | 0.5 (range 0–3.4) | 0 | P = 0.002 |
| Hospitalization days/y | 0.2 (range 0–18) | 0 | P = 0.019 |
Subjective health (SF-36)
- Numerical increase in subjective health scores following CSHI use
Remained on CSHI at study conclusion
- Remained on CSHI based on personal preference and tolerability
- 84.8%
Safety
Cardiometabolic outcomes
- No significant differences in change in weight, blood pressure, diabetes, cardiovascular/cerebrovascular events, total cholesterol, LDL and/or TG pre vs post CSHI
Original publication
Continuous Subcutaneous Hydrocortisone Infusion in Adrenal Insufficiency: Practical Experience in 33 Subjects. Endocr Pract. Published 13 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →